
LuisA.García-Rodríguez,MD
DavidGaist,MD
JonathanMorton,PhDCharlotteCookson,PhDAntonioGonzález-Pérez,MS
ABSTRACT
Objective:Toinvestigatetherelationshipbetweenhemorrhagicstrokeanduseofantiplatelets
andwarfarinusingdatafromTheHealthImprovementNetwork.
Methods:Atotalof1,797incidentcasesofintracerebralhemorrhage(ICH)and1,340ofsubarach-noidhemorrhage(SAH)wereascertained.Density-basedsamplingwasusedtoselect10,000con-trolsfreefromhemorrhagicstroke.Riskofhemorrhagicstrokewasevaluatedincurrentusersandnonusersofantiplateletsandwarfarin.Unconditionallogisticregressionmodelswereusedtoadjustforage,sex,calendaryear,alcohol,bodymassindex,hypertension,andhealthservicesutilization.
CorrespondencetoDr.García-Rodríguez:lagarcia@ceife.es
Results:AspirinusewasnotassociatedwithanincreasedriskofICH(oddsratio[OR]1.06,95%
confidenceinterval[CI]0.93–1.21),butwasassociatedwithadecreasedriskofSAH(OR0.82,95%CI0.67–1.00),comparedwithnotherapy.Aspirinuse$3yearswasassociatedwithadecreasedriskofSAH(OR0.63,95%CI0.45–0.90)comparedwithnotherapy.WarfarinusewasassociatedwithagreatlyincreasedriskofICH(OR2.82,95%CI2.26–3.53)andamoderatelyincreasedriskofSAH(OR1.67,95%CI1.15–2.43)comparedwithnotherapy.Internationalnor-malizedratiovalues$3carriedamarkedriskofICH(OR7.01,95%CI4.10–11.99).
Conclusion:AspirinisnotassociatedwithariskofICHcomparedwithnotherapy.Chroniclow-doseaspirintreatmentmayhaveaprotectiveeffectontheriskofSAH.WarfarinusersinthisstudycohortwereatamuchhigherriskofICHthanthosereceivingnotherapy,withamarkedassociationwithinternationalnormalizedratio.3.Neurologyâ2013;81:566–574
GLOSSARY
CI5confidenceinterval;ICH5intracerebralhemorrhage;INR5internationalnormalizedratio;OR5oddsratio;PCP5primarycarephysician;SAH5subarachnoidhemorrhage;THIN5TheHealthImprovementNetwork.
Seepage559Supplementaldataatdoc.guandang.net

Hemorrhagicstrokeencompassesbothprimaryintracerebralhemorrhage(ICH)andsubarach-noidhemorrhage(SAH).Theincidenceoftheseeventshasbeenreportedas24.6per100,000person-yearsand9.1per100,000person-years,respectively.1,2Hemorrhagicstrokeconstitutesapproximately10%to20%ofallstrokes,andthecase-fatalityrateat1monthinpatientswhoexperienceICHorSAHiscloseto50%.1,3
Antithromboticdrugshavebeenreportedtoincreasetheriskofintracranialstrokeandhemor-rhagicstrokerelativetonotreatment.4–12However,studiesdirectlycomparingtheriskofhem-orrhagicstrokeinpatientsreceivinganticoagulanttreatment,antiplateletdrugs,orcombinationsofthesetherapiesarescarce,especiallywhencomparedwiththelargevolumeofliteratureonriskofuppergastrointestinalbleedingassociatedwiththeuseofantiplateletdrugs.13–15StudiespresentingcombineddataonICHandSAHriskfactorsinthegeneralpopulationarerare,16andfindingsfromexistingstudiesontrendsintheincidenceofhemorrhagicstrokeinpatientsreceivingantithromboticsareconflicting,particularlyforSAH.5,10,17–20
Theaimofthisstudywastoinvestigatetherelationshipbetweenuseofantiplateletdrugsandwarfarinandhemorrhagicstrokesubtypesinthegeneralpopulation,usingdatafromTheHealthImprovementNetwork(THIN)database.
FromtheSpanishCentreforPharmacoepidemiologicResearch(CEIFE)(L.A.G.-R.,A.G.-P.),Madrid;AndalusianBioinformaticsResearchCenter(CAEBi)(A.G.-P.),Seville,Spain;NeurologyDepartment(D.G.),OdenseUniversityHospitalandInstituteofClinicalResearch,FacultyofHealthSciences,UniversityofSouthernDenmark,Odense,Denmark;andResearchEvaluationUnit(J.M.,C.C.),OxfordPharmaGenesisLtd.,Oxford,UK.GotoNeurology.orgforfulldisclosures.Fundinginformationanddisclosuresdeemedrelevantbytheauthors,ifany,areprovidedattheendofthearticle.
566©2013AmericanAcademyofNeurology
重要病理生理机制 治疗的关键在于:对于血栓的处理及干预 溶栓 抗栓 抗血小板 ...仅轻度增加症 状性颅内出血的风险 目前无评价其他抗血小板药物在脑卒中急性期...
抗血小板药物在缺血性脑卒中的临床应用_临床医学_... 350 所有卒中 缺血性卒中 出血性卒中 300 250 ...抗栓治疗 2010中国缺血性卒中/TIA二级预防指南推荐抗...
抗栓药物与出血性卒中 暂无评价 9页 2下载券 心房颤动的药物抗栓治疗... ...抗栓药物 促血栓的形成因素 ●血管壁的损伤 机械因素、感染、 化学、免疫 ●...
9版抗栓治疗和血栓形成预防 临床实践指南(ACCP9)对于急性缺血性卒中或TIA患者,...复发性 溃疡、胃肠道出血史;与抗凝药合用;对于肾功能或心血管循环受损的患者,...
缺血性卒中的抗栓治疗 董可辉 首都医科大学附属北京天坛医院 天坛脑血管病中心 卒中是多病因构成的临床综合征 卒中的分类及病因卒中 原发性出血 ?脑出血 ?蛛网膜...
3.1 在颅内出血患者用间歇充气加压装置预 4.1 对于非心源性栓塞性TIA或卒中患者脑缺 血事件的预防 抗血小板聚集药与安慰剂或与 其他替代的抗血小板药的对比 4...
该分型也奠定了此后临床研究和实践中选择不同 抗栓药物的基础。 经典TOAST分... 他汀未增加脑出血风险终点心血管死亡 非出血性脑血管事件 出血性卒中 致死性...
新型抗栓药物:循证依据不断充实_临床医学_医药卫生_专业资料。新型抗栓药物:...结果显 示,治疗 90d,两组出血性卒中发生率相同,而双联抗血小板药物治疗组卒中...
引 起不可预知的药代动力学和药效学特性,并引发非出血性副反 应,如肝素诱导...房颤的抗栓治疗对于具有高危卒中风险(CHADS2得分 ≥2)的房颤患者,口服抗凝药是...
? ? 急性冠脉综合征 缺血性卒中 外周动脉性疾病 注意事项 ? ? 观察出血体征 ...抗栓药物的主要不良反应药物 不良反应 共同阿斯匹林 氯吡格雷 肝素 不同胃肠道...
热门文档